Skip to main content

Advertisement

Table 3 Demographic and baseline data of the pooled sample

From: Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

  Placebo-controlled studies All studies
Characteristics Children (N = 275) Adolescents (N = 112) p-value Children (N = 611) Adolescents (N = 183) p-value
Gender    0.45    0.152
   Female (n, %) 44 (16.0) 16 (14.3)   115 (18.8) 21 (11.5)  
   Male (n, %) 231 (84.0) 96 (85.7)   496 (81.2) 162 (88.5)  
Age, mean (SD), y 8.7 (1.53) 13.0 (1.04) NA 8.7 (1.51) 13.0 (0.99) NA
ADHD subtype    0.002    <0.001
   Combined (n, %) 223 (81.1) 72 (64.3)   508 (83.1) 133 (72.7)  
   Hyperactive/impulsive (n, %) 10 (3.6) 7 (6.3)   14 (2.3) 10 (5.5)  
   Inattentive (n, %) 42 (15.3) 33 (29.5)   89 (14.6) 40 (21.9)  
ADHD-RS, mean (SD)       
   Total score 41.4 (7.42) 38.4 (7.83) 0.002 42.1 (7.87) 41.0 (8.57) 0.004
   Inattentive subscore 21.6 (3.70) 21.9 (3.85) 0.35 22.1 (3.80) 22.5 (3.90) 0.374
   Hyperactive/impulsive subscore 19.8 (5.51) 16.5 (6.53) <0.001 20.0 (5.79) 18.4 (6.67) <0.001
  1. p-value based on two-way analysis of variance (ANOVA) including terms age and study for continuous variables and based on Cochran-Mantel-Haenszel test controlling for study for categorical variables
  2. Abbreviations: SD, standard deviation; ADHD, attention deficit/hyperactivity disorder; ADHD-RS, Attention Deficit/Hyperactivity Disorder Rating Scale; NA, Not Applicable